We are pleased to announce the launch of our fully updated ACC Physicians List containing current information for over 850 physicians globally with experience in treating ACC.

The fully searchable database allows patients to locate physicians by name, location, institution, or field of expertise to help inform their decisions in selecting doctors. New features include a link to each doctor’s institutional website, where available, and a link to the National Physicians Index (NPI) listing for each doctor based in the USA which provides current information on practice locations and status.

This list is constantly evolving, and we rely on patient input to ensure that our database is as comprehensive and current as possible.



Please email us at info@accrf.org if any of the following apply:

• You feel your doctor is knowledgeable about ACC and should be added to the list
• Your doctor on the list has retired
• Your doctor on the list has moved away from where s/he is listed

Your guidance will ease the path for future ACC patients. We are particularly interested in countries and regions with relatively few available physicians listed.



Clinical Trial Updates

We are proud to support many oncologists in their ongoing work towards new treatments and a cure for ACC. The ACCRF research network continues to facilitate cutting-edge research and clinical trials that advance our understanding of the disease. ACCRF’s Open Studies webpage lists clinical trials that may be appropriate for ACC patients after consulting with their physicians.

Studies that recently opened, restarted, or expanded recruitment:

• REM-422 A clinical trial of a MYB inhibitor drug (REM-422) for recurrent/metastatic ACC patients is now open in Boston at Dana-Farber. More sites across the USA will open over the coming month. ACCRF is pleased to have helped Remix Therapeutics advance this study to the clinic.

• OBT-076 A clinical trial of OBT-076, an antibody drug conjugate that targets CD205, is now open in Bordeaux, France for ACC patients with progressing recurrent/metastatic disease.

Studies that have recently been closed or paused:

• KB-0742: a study of this CDK9 inhibitor recently completed and enrollment and closed.

• Amivantamab: a study of this EGFR inhibitor recently paused enrollment during an interim data analysis.

Studies with results that have recently been published:

• PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study: ACCRF grantees Drs. Ferrarotto, Swiecicki, Kang and Hanna published on a clinical trial of the PRTM5 inhibitor PRT543 in ACC.

• A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104): ACCRF grantee Dr. Ho published on a clinical trial of MK-2206 in ACC.

Recently published articles

• Lacrimal Gland Adenocarcinoma Clinicopathologic Features and Outcomes Compared With Those of Lacrimal Gland Adenoid Cystic Carcinoma: ACCRF grantees Drs. Esmaeli and Ferrarotto published on lacrimal gland ACC clinicopathological features and outcomes.

• The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma: ACCRF grantees Drs. Sala and Stenman published work identifying BUB1 as a targetable kinase downstream of MYB.

• Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance: ACCRF grantees demonstrated the relevance of B7H4, a new target in ACC, with related clinical trials open and pending.

• Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma: ACCRF grantee Dr. Keam published on the relationship between the immune system and whether the drug Axitinib slows ACC metastases.

These and other important research papers are all listed on our Published Articles webpage.